Exelixis Inc (EXEL)
21.23
-1.03 -4.63%
NASDAQ
Feb 19, 13:53
Delayed 2m
USD
View All Key Stats
EXEL Key Stats
| Income Statement | |
| Revenue (TTM) | 852.45M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | 2.21 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | 690.07M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 96.78% |
| Profit Margin (Quarterly) | 56.18% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | Upgrade |
| Price and Valuation | |
| Market Cap | 6.347B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | 7.787 |
| PE Ratio (TTM) | 9.606 |
| Price to Book Value | 4.930 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | Upgrade |
| Free Cash Flow (Quarterly) | 149.33M |
| Return on Equity (TTM) | Upgrade |
View All EXEL News
EXEL News
-
WireHeadlineTime (ET)
-
SA Breaking News02/19 09:46
-
Yahoo02/19 07:17
-
Yahoo02/15 06:52
-
Yahoo02/14 08:40
-
Yahoo02/13 18:51
-
MT Newswires02/13 15:48
-
Yahoo02/13 15:47
-
MT Newswires02/13 15:07
-
MT Newswires02/13 13:57
-
Yahoo02/13 13:25
View All Events
EXEL Events
| Date | Type | Description |
|---|---|---|
| 05/02/2019 17:00 EDT | Misc | Exelixis Inc First Quarter Earnings Conference Call in 2019 |
| 05/02/2019 | Earnings | Exelixis Inc First Quarter Earnings in 2019 Release |
| 02/12/2019 17:00 EST | Misc | Exelixis Inc Fourth Quarter Earnings Conference Call in 2018 |
| 02/12/2019 | Earnings | Exelixis Inc Fourth Quarter Earnings in 2018 Release |
| 11/01/2018 17:00 EDT | Misc | Exelixis Inc Third Quarter Earnings Conference Call in 2018 |
| 11/01/2018 | Earnings | Exelixis Inc Third Quarter Earnings Results in 2018 |
| 08/01/2018 17:00 EDT | Misc | Exelixis Inc Second Quarter Earnings Conference Call in 2018 |
| 08/01/2018 | Earnings | Exelixis Inc Second Quarter Earnings Results in 2018 |
| 05/23/2018 | Misc | Exelixis Inc Annual General Meeting in 2017 |
| 05/02/2018 17:00 EDT | Misc | Exelixis Inc First Quarter Earnings Conference Call in 2018 |
EXEL Fundamentals
Income Statement View Statement
EXEL Ratings
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
Advertisement
EXEL One Page Reports
- One Page Report Download
EXEL Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 21.23 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Edit
Profile
- URL: http://www.exelixis.com
- Investor Relations URL: http://www.exelixis.com/investors-media
- HQ State/Province: California
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Mid Cap/Growth
- Next Earnings Release: May. 02, 2019
- Last Earnings Release: Feb. 12, 2019
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma. The company has partnerships with larger pharmaceutical and biotech firms to develop its pipeline, including Bristol, Sanofi, and Merck.
EXEL Excel Add-In Codes
- Name: =YCI("EXEL","name")
- Description: =YCI("EXEL","description")
- Sector: =YCI("EXEL","sector")
- Industry: =YCI("EXEL","industry")
- Est. Current Fiscal Year End: =YCI("EXEL","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Other EXEL Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- EXEL Tweets Stocktwits
Advertisement
